Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + regorafenib + raltitrexed for previously treated MSS/pMMR metastatic colorectal cancer
ChiCTR2500103962Phase 4Recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, regorafenib and raltitrexed in colorectal cancer (CRC), sponsored by Army Medical Center of PLA. Primary endpoint: Progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
tislelizumabregorafenibraltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500103962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103962.